Cardiology in Review

Skip Navigation LinksHome > January/February 2009 - Volume 17 - Issue 1 > Antiretroviral and Statin Drug-Drug Interactions
Cardiology in Review:
doi: 10.1097/CRD.0b013e3181903b7f
Curbsite Consult

Antiretroviral and Statin Drug-Drug Interactions

Ray, Gretchen M. PharmD

Collapse Box


Patients living with the human immunodeficiency virus (HIV) are at risk for dyslipidemia as a result of the disease itself and from certain classes of antiretroviral therapy. The protease inhibitors and non-nucleoside reverse transcription inhibitors have been associated with elevated triglycerides, total, and low-density lipoprotein cholesterol with decreased high-density lipoprotein. These classes of medications affect the cytochrome P450 (CYP) enzyme resulting in both induction and inhibition of numerous CYP enzymes. The statins are extensively metabolized by the CYP system and therefore drug-drug interactions between the statins and antiretroviral therapy must be considered when treating HIV or antiretroviral drug-induced dyslipidemia.

© 2009 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.